Continuing Education Activity

Proteinuria is a very common finding in outpatient as well as inpatient settings. Any such results warrant further investigation, especially in the setting of comorbidity. Given the rising trends of diabetes, proteinuria prevalence is on the rise. The primary etiology of proteinuria is the disturbance in the kidney filter. In addition to its association with early renal disease, it is also seen in benign conditions. Proteinuria has now also been used along with the estimated glomerular filtration rate (eGFR) in the classification of chronic kidney disease (CKD). Proteinuria can serve as an indicator of early renal disease. It marks an increased risk of renal damage secondary to hypertension and cardiovascular disease. The degree of proteinuria correlates with disease progression. This activity reviews the evaluation and management of proteinuria and explains the role of the interprofessional team in improving care for patients with this condition.

Objectives:

• Identify the etiology of proteinuria.
• Explain the evaluation of proteinuria.
• List the management options available for proteinuria.
• Summarize interprofessional team strategies for improving care coordination and communication in patients with proteinuria to ensure the best outcomes.

Introduction

Proteinuria is a broad term used to describe protein in the urine. It is a general term for the presence of proteins, including albumin, globulin, Bence-Jones protein, and mucoprotein in the urine.[1] Almost half of the protein lost in normal urine is derived from the distal tubule, known as Tamm-Horsfall glycoprotein (THG).[2][3] Persistent proteinuria is a marker of kidney damage. It also helps with the diagnosis, prognosis, and therapy.[4][5]

The primary etiology of proteinuria is the disturbance in the kidney filter. In addition to its association with early renal disease, it is also seen in benign conditions.[6][7] Proteinuria has now also been used along with the estimated glomerular filtration rate (eGFR) in the classification of chronic kidney disease (CKD).[8] Proteinuria can serve as an indicator of early renal disease. It marks an increased risk of renal damage secondary to hypertension and cardiovascular disease.[9] The degree of proteinuria correlates with disease progression.[10]

According to the UK chronic kidney disease guidelines, proteinuria is defined as a urine protein creatinine ratio (UPCR) of more than 45 mg/mmol, but this does not warrant further evaluation in the absence of hematuria unless the UPCR is more than 100 mg/mmol.[3]

According to the NICE guidelines, proteinuria is defined as a UPCR of more than 50 mg/mmol or a urine albumin creatinine ratio (UACR) of more than 30 mg/mmol.[3][11]

Etiology

Proteinuria can be classified as transient and persistent.

Transient Proteinuria

• Urinary tract infection
• Orthostatic proteinuria (occurs after the patient has been upright for a prolonged period, absent in early morning urine) - this is rare in patients more than 30 years of age[12]
• Fever
• Heavy exercise
• Vaginal mucus
• Pregnancy[9]

Persistent Proteinuria

• Primary renal disease

  • Glomerular (such as glomerulonephritis)
  • Tubular[13]
• Secondary renal disease

  • Diabetes mellitus
  • Connective tissue diseases 
  • Vasculitis
  • Amyloidosis
  • Myeloma[14]
  • Congestive cardiac failure
  • Hypertension[9]

Benign Causes of Proteinuria

• Fever
• Acute illness
• Exercise/intense physical activity[15]
• Orthostatic proteinuria[8]
• Dehydration
• Emotional stress
• Hear injury
• Inflammatory process[5]

The benign causes of proteinuria do not increase morbidity or mortality otherwise. These conditions are highly variable and usually reversible as the precipitating factor is addressed. Proteinuria is not a part of normal aging.[5]

Epidemiology

The prevalence of proteinuria in the general population lies between 8% and 33%. The broad range is due to the variety of methods used to report proteinuria.[16][17][18] Due to its high prevalence, Japan has a screening program for proteinuria.[19][20] One of the major causes of renal disease and resultant proteinuria is the growing prevalence of type 2 diabetes mellitus. The prevalence of persistent proteinuria in affected individuals has been reported to be 15.3 per 1000 person-years. Less than 2% of patients with positive urine dipstick have a serious underlying etiology or urinary tract infection.[5] In the US, 3.3% of the adult population was observed to have persistent albuminuria with a normal eGFR.[21]

Race

In a survey, it was found that the prevalence of microalbuminuria is greater in non-Hispanic Blacks and Mexican Americans compared with non-Hispanic Whites.[22]

Sex

Most primary and secondary renal diseases are more common in males than females. Persistent proteinuria is twice as common in males as in females.

Age

Due to the increase in the incidence of hypertension and diabetes with age, persistent proteinuria and microalbuminuria also increase with age.

Pathophysiology

Proteinuria is a result of three different pathways, including:

1. Glomerular dysfunction
2. Tubulointerstitial disease
3. Secretory proteinuria
4. Overflow proteinuria

Glomerular Dysfunction

This is the most common cause of proteinuria. Glomerular dysfunction alters the permeability of the glomerular basement membrane leading to albuminuria and immunoglobinuria. Glomerular dysfunction causes urinary protein excretion of more than 2 g/24-hour.[5]

The glomerular filtration barrier is a three-layer membrane structure with the following layers (inner to outer):

1. Fenestrated glomerular endothelium
2. Glomerular basement membrane
3. Podocyte[23]

The basement membrane of the glomerular capillary wall is responsible for restricting protein filtration owing to the presence of type 4 collagen. This filtration restriction is weight and size-based. As a result, larger and heavier proteins like albumin (molecular weight of 69000 D) are not seen in the urine under normal circumstances. In addition to the size and weight barrier, the negative charge on the glomerular capillary wall prevents the passage of negatively charged proteins like albumin.[1]

Glomerular proteinuria results from a damaged glomerular filtration barrier or increased hydrostatic pressure. Dysfunction of the charge barrier that consists of collagen and laminin leads to a loss of the negative charge, which manifests in the appearance of negatively charged proteins in the urine. In addition, mesangial cell growth in the glomerulus, extracellular matrix production, and infiltration with inflammatory cells can also lead to proteinuria. Podocytes are an essential barrier to proteinuria, and molecular dysfunction of nephrin and podocin at the level of podocytes can lead to the development of proteinuria. Transient receptor potential cation (TRPC) is a protein involved in calcium influx and has been shown to be associated with podocyte injury through an NFAT-mediated signaling pathway. The kidney also produces a membrane protein known as Klotho. In a recent study, klotho has been shown to suppress TRPC and hence may offer a therapeutic benefit for proteinuria in the future.[23]

Causes of glomerular dysfunction include:

• Diabetic nephropathy (most common)
• Drug-induced nephropathy (NSAIDs, lithium, heavy metals, heroin)[24]
• Lymphoma[25]
• Infections (HIV, hepatitis B, and C)
• Primary glomerulonephropathies
• Amyloidosis
• Malignancies[5]
• Dyslipidemia
• Reactive oxygen species
• Inflammatory cytokines
• Activation of the renin-angiotensin system (RAS)[23]
• Connective tissue diseases such as SLE

Chronic proteinuric glomerulopathy is defined as a sustained or permanent loss of protein filtration selectivity of the glomerulus.[23]

Tubulointerstitial Dysfunction

This is due to the dysfunction at the proximal tubule resulting in the impairment of the uptake of filtered proteins. Tubulointerstitial dysfunction usually leads to less severe proteinuria than glomerular dysfunction, with 24-hour urine protein levels of less than 2 grams.[5]

Smaller and positively charged proteins usually filtered through the glomerular capillary are absent in the urine owing to the nearly complete reabsorption by the tubular epithelial cells. Most of the protein reabsorption occurs in the proximal convoluted tubules. This reabsorption in the proximal convoluted tubules has a transport maximum which, when reached, can result in proteinuria.[1]

Causes of tubular dysfunction include:

• Hypertensive nephrosclerosis
• NSAIDs induced nephropathy[5]
• Nephrotoxins
• Chronic tubulointerstitial disease[1]

Secretory Proteinuria

Secretory proteinuria results from the oversecretion of specific proteins in the tubules, the most notable one being the Tamm-Horsfall proteins in interstitial nephritis.

Overflow Proteinuria

Increased production of proteins can saturate the reabsorptive channels in the proximal convoluted tubules leading to proteinuria. Overflow proteinuria occurs when the plasma concentration of low-molecular-weight proteins goes beyond the tubular capacity to reabsorb the filtered proteins.[26] Causes of overflow proteinuria include:

• Multiple myeloma
• Myoglobinuria
• Amyloidosis[5]

History and Physical

Proteinuria may be asymptomatic, many patients do not report any symptoms, and proteinuria is detected on routine laboratory examination. A thorough history should be obtained from the patient, mainly asking about the symptoms of renal failure, including leg swelling and weight changes, as well as symptoms of connective tissue diseases, including arthralgias, skin rashes, and mouth ulcers.[27] Patients should be asked about loin pain, abdominal pain, shortness of breath, pleuritic chest pain, or rigors. A history of changes in the urine’s appearance (red/smoky, frothy) and its relation to an upper respiratory tract infection should also be obtained. In addition, a detailed history of comorbid conditions, including hypertension, diabetes mellitus, heart failure, etc., is required.

Thorough drug history is essential to rule out any nephrotoxic drug currently being used or used in the past as a possible cause of proteinuria. These include but are not limited to non-steroidal anti-inflammatory drugs (NSAIDs), antihypertensive drugs including angiotensin-converting enzyme (ACE) inhibitors, loop diuretics, and various antibiotics, especially penicillamine, aminoglycosides, and over-the-counter herbal medicines.[28] Detailed family history is essential to rule out familial renal and connective tissue diseases. The physical examination should focus on edema, muscle wasting, rashes, abdominal bruits, and splinter hemorrhages. On examination, there may be signs of systemic disease, e.g., retinopathy, joint swelling or deformity, stigmata of chronic liver disease, cardiac murmurs, organomegaly, and lymphadenopathy. Measurement of blood pressure can also help in making a diagnosis.[9]

Evaluation

Evaluation of a patient with proteinuria should begin with excluding urinary tract infection and the presence of diabetes mellitus. Urine dipsticks are the first screening tests for proteinuria that can be performed in an office. This is a semi-quantitative test in addition to being a qualitative test. The reading of proteinuria on a urine dipstick should be interpreted, considering the concentration of the urine reflected by the specific gravity. For instance, a urine dipstick value of 11 in a well-hydrated patient producing large quantities of dilute urine represents far more severe proteinuria than a dehydrated patient with similar values on a dipstick. The urine dipstick is semi-quantitative because although a reading of 11 on a dipstick shows proteinuria greater than 1 g/24 hour, it does not signify how much the value is greater than 1 g/24 hour.[8]

The urine dipstick diagnostic pad usually contains tetra bromophenol blue and citrate buffers. Several other dyes are also available that are more specific to albumin.[8][29][30] The pad detects the protein due to its electronegativity by changing color from yellow to blue. The mechanism used for protein detection by dipsticks should be considered because few proteins have a positive charge, like immunoglobulins. As a result, they are not detected on a urine dipstick. This problem can be solved using sulfosalicylic acid (SSA), which can detect immunoglobulins by flocculating. Similarly, alkaline urine will also change the color of the dipstick, giving a false positive.[30] Any positive results on dipstick and SSA should be further evaluated promptly.

Urine Dipstick Readings

False Positive

• Dehydration
• UTI
• Hematuria
• Alkaline urine pH of more than 8
• Recent exercise

False Negative

• Overhydration
• Positively charged proteins (light chains)[8]

In order to quantify the degree of proteinuria, a 24-hour urine collection is entirely accurate but cumbersome to calculate the 24-hour urinary protein excretion in mg per 24 hours. Any value greater than 150 mg/24 hours is considered abnormal and should be further evaluated for underlying reasons.[9] The 24-hour urine collection is quite susceptible to overcollection or under-collection errors.[8]

An easier and reliable alternative is the spot urine protein to creatinine ratio (UPCR) from a single specimen, which should preferably be the early morning urine sample. [(mg/l protein)/(mmol/l creatinine)*10]. A UPCR value greater than 15 mg/mmol should raise suspicion and warrant further investigation.[9]

In addition to the protein levels, serum electrolytes, urea, and creatinine should be checked. For a nephrotic range of proteinuria with more than 3.5 g/24-hours or a UPCR of more than 350 mg/mmol, the serum albumin levels and cholesterol concentrations should be checked.[31] The value of proteinuria should be correlated with renal function tests. For example, a patient with UPCR values within normal limits with abnormal renal function tests, hematuria, and comorbidities should be evaluated.

Creatinine clearance is more helpful in evaluating renal function than creatinine levels. This can be calculated using some equations, such as the modification of diet in renal disease (MDRD), CKD-EPI equation, and the Cockcroft-Gault formula (as follows).

Creatinine clearance (ml/min) = [(140-age) X weight (kgs) X C] / serum creatinine (mol/l);

where C is 1.23 in males and 1.04 in females.

Normal creatinine clearance for a healthy young adult is more than 90 ml/min. It changes as the muscle mass changes in elderly patients and bodybuilders.[9] With aging, there is a decrease in creatinine clearance by 0.75 ml/min/year.[5][32] As a result, age and muscle mass should be considered with these values. For healthy adult males, the creatinine excretion ranges from 20 to 25 mg/kg/24 hours, whereas females excrete about 15- 20 mg/kg/24 hours. A healthy adult male of 70 kg will have 1400 to 1850 mg of creatinine excretion daily.[8]

Imaging (particularly renal ultrasonography), immunology screen (ANA, ANCA), and viral screen (hepatitis B and C ) are also helpful in diagnosing the underlying cause.[33]

Degrees of Proteinuria

• Normal: Less than 150 mg/24 hour or 15 mg/mmol
• Nephritic: 150-3000 mg/24 hour or 12-300 mg/mmol
• Nephrotic: More than 3500 mg/24 hour or more than 350 mg/mmol

The type of protein constituting the proteinuria can be determined by immunoelectrophoresis.[34]

Albuminuria (mg/d)

• Normal: Less than 30
• Microalbuminuria: 30-300
• Macroalbuminuria: More than 300[8]

Other Tests

• Autoantibody determinations - including antistreptolysin O titers, antinuclear antibodies (ANAs), anti-DNA antibodies, complement levels (C3 and C4), anti-phospholipase A1 receptor autoantibody, and cryoglobulins
• Hepatitis B and C and HIV serologies
• Urine and plasma protein electrophoresis for light chains
• Anti–glomerular basement membrane (anti-GBM) antibodies and antineutrophil cytoplasmic antibodies (ANCA)

Imaging Studies

• Renal ultrasonography to review the size and echogenicity of the kidneys
• Chest radiography or computed tomography may also be indicated

Renal Biopsy

Renal biopsy should be considered in patients with proteinuria above 1 g per day because it can guide the choice of a specific therapy.

Treatment / Management

The treatment of proteinuria is mainly focused on treating the specific underlying cause. In addition, most treatment modalities focus on reducing the degree of proteinuria, particularly albuminuria. These include drugs acting on the renin-angiotensin-aldosterone system. The 2013 Kidney Disease Improving Global Outcomes (KDIGO) guideline strongly recommends using ACE inhibitors or angiotensin receptor antagonists (ARB) in adults with more than 300 mg/24 hours of persistent proteinuria. The Chronic Kidney Disease Management publication by Kidney Health Australia in 2015 set the treatment target as a 50% reduction in albuminuria.[35]

Data obtained from multiple efficacy trials have shown the effectiveness of ACE inhibitors in reducing proteinuria in diabetic and nondiabetic patients. In addition to their effect on proteinuria, they have effectively reduced the risks of renal disease progression and hence, the requirement for renal replacement therapy.[36][37] As advised by Kidney Health Australia, the target of reducing proteinuria by 50% in the first six months to a year is associated with a similar decrease in the risk of renal disease progression.[35][38]

A study has shown that the efficacy of ACE inhibitors in halting the progression of proteinuria is more significant in patients with higher quantities of proteinuria than those with lower amounts of protein in the urine.[5][39] The initiation of therapy with ACE inhibitors requires a close check on creatinine and potassium levels. The current data does not show any significant difference between the efficacy and side effect profiles of both ACE inhibitors and ARBs. Hence the decision should be guided by the patient’s response and the provider’s experience.[35]

Combination therapies of ACE inhibitors with ARBs and direct renin inhibitors have been trialed in multiple studies showing an increased risk of adverse effects, including hyperkalemia, hypotension, renal impairment, and syncope.[40] Data is insufficient to recommend a combination of ACE and ARB to prevent any progression of renal disease. The Kidney Health Australia and the NICE guidelines in the UK do not recommend combination therapy for progression prevention in proteinuria.[35]

Diuretics

Patients with moderate to severe proteinuria have fluid overload and require diuretic therapy and dietary salt restriction. Aldosterone antagonists have also shown an advantage in their efficacy for proteinuria.[35] Combination therapy of ACE inhibitors with aldosterone antagonists is associated with an increased risk of hyperkalemia and gynecomastia. However, this combination has shown significant mortality benefits in patients with heart failure.[35][41]

Calcium Channel Blockers

Non-dihydropyridine calcium channel blockers (NDCCBs), diltiazem, and verapamil decrease proteinuria greater than dihydropyridine calcium channel blockers (DCCBs). The newer NDCCBs, such as efonidipine and benedipine, used in combination with ARBs, have reduced proteinuria.[42][43]

Differential Diagnosis

The presence of proteinuria in a patient requires a thorough evaluation and appropriate management to avoid developing complications.[1][5][8] The following differential diagnoses should be considered in a patient with proteinuria.[9][44][45]

• Diabetic nephropathy
• Orthostatic proteinuria
• Nephrotoxins, drug-induced nephropathy (NSAIDs, lithium, heavy metals, heroin)
• Infections (urinary tract infection, HIV, hepatitis B, and C)
• Primary glomerulonephropathies, chronic tubulointerstitial disease
• Amyloidosis
• Post renal transplant
• Preeclampsia
• Malignancies (myeloma, lymphoma)
• Dyslipidemia
• Connective tissue diseases
• Vasculitis
• Congestive cardiac failure
• Hypertension
• Dehydration
• Exercise/intense physical activity
• Emotional stress

Prognosis

Studies have suggested that early recognition and management play a vital role in the prognosis of patients with proteinuria.[5] Proteinuria is used to assess the prognosis of many diseases. Proteinuria in IgA nephropathy is associated with a worse patient outcome.[46]

Similarly, higher proteinuria is correlated with a poor prognosis in patients with chronic kidney disease.[47] In idiopathic membranous nephropathy, the presence of proteinuria also reflects a poor prognosis.[48] Post-renal transplantation proteinuria is associated with higher mortality and reduced graft survival.[45] In a patient with preeclampsia, proteinuria reflects worse outcomes for both the mother and the fetus.[44]

Complications

Proteinuria is associated with significant complications, including increased risks of:

• Coronary heart disease
• Cerebrovascular disease[49][50]
• Gastrointestinal hemorrhage[51]
• Progression of kidney disease[52]
• Hypercoagulability, Venous thromboembolism[53]
• Pulmonary edema due to fluid overload
• Bacterial infections
• Renal replacement therapy, including dialysis and transplant
• Death[5][35][54]

Studies have shown that microalbuminuria increases the risk of coronary artery disease by 50%, whereas the risk of cerebrovascular disease is increased by 70%. Macro-albuminuria is associated with doubling the risk for both.[35]

Consultations

In addition to thorough evaluation and referral to a nephrologist, any patient with proteinuria should be assessed periodically, preferably every six months, while managing hypertension, diabetes, and other comorbidities.[9] A patient with proteinuria may require the following consultations during their diagnostic workup and management of the underlying factors and complications.

• Nephrologist
• Immunologist
• Endocrinologist
• Cardiologist
• Neurologist
• Gastroenterologist
• Transplant team (transplant nephrologist, transplant surgeon, nurse, social worker, psychiatrist)

Deterrence and Patient Education

The urine collection over 24 hours requires that the urine collection process be educated to the patient clearly with clear written instructions.[8] The patient should be warned about the likely adverse effects of ACE inhibitors and angiotensin receptor blockers, including angioedema, dizziness, cough, syncope, hypotension, hyperkalemia, and a slightly increased risk of lung cancer.[35] Patients with moderate to severe proteinuria are in a fluid overload state, so salt restriction is also advised.

Enhancing Healthcare Team Outcomes

Proteinuria has no traditionally set cut-off values, varying from 150 to 300 mg/24 hours, depending upon the laboratory.[3] Any potential nephrotoxic drug should preferably be replaced if possible, or dosage adjustments should be made. In a patient with coexistent hypertension or heart failure, angiotensin-converting enzyme or angiotensin 2 receptor blockers should be the first line of management.[9]

An approach that is likely to benefit the patients is the gradual titration of ACE inhibitor or ARB dosages in increments, considering the patient’s individual response to drug tolerance and adverse effects.[35] Management of a patient with proteinuria requires an interprofessional team consisting of clinicians, nursing staff, nurses, pharmacists, and laboratory technicians. To accurately determine the underlying cause in these patients, open communication between all team members and specialties is crucial to getting the patient managed as expediently as possible. This also includes accurate record-keeping. This interprofessional approach utilizing open communication channels is necessary for optimal patient outcomes. [Level 5]

Screening

It is recommended to screen adults for one or more of the following risk factors:

• Chronic kidney disease
• Diabetes
• Hypertension
• Obesity
• Current smoking
• Cardiovascular disease
• Family history of chronic kidney disease
• Aboriginal or Torres Strait Islander people[35]

Screening is recommended because early recognition and management are associated with better outcomes regarding reduced morbidity and mortality.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Grauer GF. Proteinuria: measurement and interpretation. Top Companion Anim Med. 2011 Aug;26(3):121-7. [PubMed: 21782142]

2.

Hoyer JR, Seiler MW. Pathophysiology of Tamm-Horsfall protein. Kidney Int. 1979 Sep;16(3):279-89. [PubMed: 393892]

3.

Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem. 2009 May;46(Pt 3):205-17. [PubMed: 19389884]

4.

Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G., National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 Jul 15;139(2):137-47. [PubMed: 12859163]

5.

Verma V, Kant R, Sunnoqrot N, Gambert SR. Proteinuria in the elderly: evaluation and management. Int Urol Nephrol. 2012 Dec;44(6):1745-51. [PubMed: 22826147]

6.

Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF., ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011 Mar 01;154(5):310-8. [PubMed: 21357908]

7.

Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, Chronic Kidney Disease Prognosis Consortium. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, de Zeeuw D, Rossing P, Parving HH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011 Jun;79(12):1331-40. [PMC free article: PMC3917543] [PubMed: 21289598]

8.

Snyder S, John JS. Workup for proteinuria. Prim Care. 2014 Dec;41(4):719-35. [PubMed: 25439530]

9.

Haynes J, Haynes R. Proteinuria. BMJ. 2006 Feb 04;332(7536):284. [PMC free article: PMC1360404] [PubMed: 16455729]

10.

Nielsen R, Christensen EI. Proteinuria and events beyond the slit. Pediatr Nephrol. 2010 May;25(5):813-22. [PubMed: 20049615]

11.

National Collaborating Centre for Chronic Conditions (UK). Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. Royal College of Physicians (UK); London: Sep, 2008. [PubMed: 21413194]

12.

Uehara K, Tominaga N, Shibagaki Y. Adult orthostatic proteinuria. Clin Kidney J. 2014 Jun;7(3):327-8. [PMC free article: PMC4377758] [PubMed: 25852903]

13.

Bökenkamp A. Proteinuria-take a closer look! Pediatr Nephrol. 2020 Apr;35(4):533-541. [PMC free article: PMC7056687] [PubMed: 31925536]

14.

Gurung R, Li T. Renal Amyloidosis: Presentation, Diagnosis, and Management. Am J Med. 2022 Apr;135 Suppl 1:S38-S43. [PubMed: 35085515]

15.

Kohler M, Schänzer W, Thevis M. Effects of exercise on the urinary proteome. Adv Exp Med Biol. 2015;845:121-31. [PubMed: 25355575]

16.

Lim D, Lee DY, Cho SH, Kim OZ, Cho SW, An SK, Kim HW, Moon KH, Lee MH, Kim B. Diagnostic accuracy of urine dipstick for proteinuria in older outpatients. Kidney Res Clin Pract. 2014 Dec;33(4):199-203. [PMC free article: PMC4714264] [PubMed: 26885477]

17.

Tomonaga Y, Risch L, Szucs TD, Ambühl PM. The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study. PLoS One. 2013;8(7):e67848. [PMC free article: PMC3700872] [PubMed: 23844110]

18.

White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis. 2011 Jul;58(1):19-28. [PubMed: 21411199]

19.

Bezinque A, Noyes SL, Kirmiz S, Parker J, Dey S, Kahnoski RJ, Lane BR. Prevalence of Proteinuria and Other Abnormalities in Urinalysis Performed in the Urology Clinic. Urology. 2017 May;103:34-38. [PubMed: 28212852]

20.

Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, Makino H, Hishida A. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008 Feb;12(1):1-8. [PubMed: 18175065]

21.

Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, Kusek JW, Byrd-Holt D, Narayan KM, Herman WH, Jones CP, Salive M, Agodoa LY. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002 Mar;39(3):445-59. [PubMed: 11877563]

22.

Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J Kidney Dis. 2006 Nov;48(5):720-6. [PubMed: 17059991]

23.

Liu D, Lv LL. New Understanding on the Role of Proteinuria in Progression of Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:487-500. [PubMed: 31399981]

24.

Gong R, Wang P, Dworkin L. What we need to know about the effect of lithium on the kidney. Am J Physiol Renal Physiol. 2016 Dec 01;311(6):F1168-F1171. [PMC free article: PMC5210210] [PubMed: 27122541]

25.

Sfrijan D, Tieranu I, Necula I, Popa L, Balgradean M. Nephrotic Syndrome, Paraneoplastic Syndrome Associated to Hodgkin Lymphoma. Maedica (Bucur). 2016 Mar;11(1):64-67. [PMC free article: PMC5394490] [PubMed: 28465754]

26.

Leung AK, Wong AH, Barg SS. Proteinuria in Children: Evaluation and Differential Diagnosis. Am Fam Physician. 2017 Feb 15;95(4):248-254. [PubMed: 28290633]

27.

Uva L, Miguel D, Pinheiro C, Freitas JP, Marques Gomes M, Filipe P. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis. 2012;2012:834291. [PMC free article: PMC3410306] [PubMed: 22888407]

28.

Ağbaş A, Bay ED, Başaran MK, İkizceli T, Kayhan GK, Özlük Y. Nephrotic range proteinuria in an adolescent with a diagnosis of Wilson's disease: Answers. Pediatr Nephrol. 2021 Jul;36(7):2103-2106. [PubMed: 33528637]

29.

WILLS MR, MCGOWAN GK. THE RELIABILITY OF THE ALBUSTIX TEST FOR PROTEINURIA. J Clin Pathol. 1963 Sep;16(5):487. [PMC free article: PMC480620] [PubMed: 14063342]

30.

Pugia MJ, Lott JA, Profitt JA, Cast TK. High-sensitivity dye binding assay for albumin in urine. J Clin Lab Anal. 1999;13(4):180-7. [PMC free article: PMC6807896] [PubMed: 10414598]

31.

Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016 Jul;90(1):41-52. [PMC free article: PMC5812444] [PubMed: 27165836]

32.

Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985 Apr;33(4):278-85. [PubMed: 3989190]

33.

Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014 Jun 28;20(24):7544-54. [PMC free article: PMC4069286] [PubMed: 24976695]

34.

Lyubimova NV, Timofeev YS, Abaev VM, Votyakova OM, Kushlinskii NE. Immunochemical Diagnosis of Multiple Myeloma. Bull Exp Biol Med. 2018 May;165(1):84-87. [PubMed: 29797132]

35.

Athavale A, Roberts DM. Management of proteinuria: blockade of the renin-angiotensin-aldosterone system. Aust Prescr. 2020 Aug;43(4):121-125. [PMC free article: PMC7450775] [PubMed: 32921887]

36.

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-62. [PubMed: 8413456]

37.

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997 Jun 28;349(9069):1857-63. [PubMed: 9217756]

38.

Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan;3 Suppl 1(Suppl 1):S3-10. [PMC free article: PMC3152266] [PubMed: 18178794]

39.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. [PubMed: 11904577]

40.

ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. [PubMed: 18378520]

41.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 02;341(10):709-17. [PubMed: 10471456]

42.

Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol. 1989 Jun;256(6 Pt 2):F1015-20. [PubMed: 2544103]

43.

Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep;54(3):889-96. [PubMed: 9734613]

44.

Tanacan A, Fadiloglu E, Beksac MS. The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes. Hypertens Pregnancy. 2019 May;38(2):111-118. [PubMed: 30939965]

45.

Tsampalieros A, Knoll GA. Evaluation and Management of Proteinuria After Kidney Transplantation. Transplantation. 2015 Oct;99(10):2049-60. [PubMed: 26335919]

46.

Reich HN, Troyanov S, Scholey JW, Cattran DC., Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007 Dec;18(12):3177-83. [PubMed: 17978307]

47.

Iimori S, Naito S, Noda Y, Sato H, Nomura N, Sohara E, Okado T, Sasaki S, Uchida S, Rai T. Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study. PLoS One. 2018;13(1):e0190493. [PMC free article: PMC5771558] [PubMed: 29342207]

48.

Chen X, Chen Y, Ding X, Zhou Y, Lv Y, Li D, Chen B, Chen T, Chen C. Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy. Ren Fail. 2019 Nov;41(1):363-369. [PMC free article: PMC6508055] [PubMed: 31057017]

49.

Naderi AS, Reilly RF. Primary care approach to proteinuria. J Am Board Fam Med. 2008 Nov-Dec;21(6):569-74. [PubMed: 18988725]

50.

Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med. 2008 Oct 21;5(10):e207. [PMC free article: PMC2570419] [PubMed: 18942886]

51.

Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic Kidney Disease and Risk for Gastrointestinal Bleeding in the Community: The Atherosclerosis Risk in Communities (ARIC) Study. Clin J Am Soc Nephrol. 2016 Oct 07;11(10):1735-1743. [PMC free article: PMC5053788] [PubMed: 27515592]

52.

Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006 Nov;17(11):2974-84. [PubMed: 17035611]

53.

Gigante A, Barbano B, Sardo L, Martina P, Gasperini ML, Labbadia R, Liberatori M, Amoroso A, Cianci R. Hypercoagulability and nephrotic syndrome. Curr Vasc Pharmacol. 2014 May;12(3):512-7. [PubMed: 22724465]

54.

Jun M, Ohkuma T, Zoungas S, Colagiuri S, Mancia G, Marre M, Matthews D, Poulter N, Williams B, Rodgers A, Perkovic V, Chalmers J, Woodward M., ADVANCE Collaborative Group. Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care. 2018 Jan;41(1):163-170. [PubMed: 29079715]

Disclosure: Mobeen Haider declares no relevant financial relationships with ineligible companies.

Disclosure: Ahsan Aslam declares no relevant financial relationships with ineligible companies.